Device Et

Auryon Laser System 100-120 Vac

Payments companies reported to CMS as associated with Auryon Laser System 100-120 Vac. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$19Massociated payments (2023-2025)
4,010clinicians with associated payments
1company reporting

By year

2023 $5.8M
2024 $6.9M
2025 $6.0M

Payments reported as associated with Auryon Laser System 100-120 Vac, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Vascular & Interventional Radiology $5.6M
Vascular Surgery $4.4M
Interventional Cardiology $2.3M
Cardiovascular Disease $2.1M
Diagnostic Radiology $791K
Surgery $561K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Auryon Laser System 100-120 Vac

These are the largest totals companies reported as associated with Auryon Laser System 100-120 Vac. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Vladimir Zeetser Encino, CA Foot & Ankle Surgery $471,267.87
Nadeer Pirani Las Vegas, NV Vascular & Interventional Radiology $235,030.34
Nazar Golewale Merrillville, IN Vascular & Interventional Radiology $216,354.83
Salar Hakham Montebello, CA Vascular & Interventional Radiology $210,967.13
Rotimi Johnson Elgin, IL Vascular & Interventional Radiology $209,491.89
Amiel Moshfegh Commerce, CA Vascular & Interventional Radiology $194,515.04
Hammad Amer Mesa, AZ Vascular Surgery $149,884.49
Thomas Hodgkiss Memphis, TN Diagnostic Radiology $149,565.42
Warren Swee West Palm Beach, FL Vascular & Interventional Radiology $148,114.67
Malwinder Singha Rancho Cucamonga, CA Vascular & Interventional Radiology $144,630.76

Prescribed Auryon Laser System 100-120 Vac?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.